STRATEC Biomedical (ETR:SBS) target price raised to 56.00EUR, issued a report today by Oddo Seydler Bank AG
- Updated: September 30, 2016
STRATEC Biomedical (ETR:SBS) had its target price raised to 56.00EUR by Oddo Seydler Bank AG in a report released 10/01/2016. The new target price indicates a possible upside of 0.10% based on the company's last closing price.
Previously on Friday September 30, 2016, Oddo Seydler Bank AG reported on STRATEC Biomedical (ETR:SBS) raised the target price from 0.00EUR to 56.00EUR. At the time, this indicated a possible upside of 0.10%.
Yesterday STRATEC Biomedical (ETR:SBS) traded -1.07% lower at 50.76EUR. The company’s 50-day moving average is 9.16EUR and its 200-day moving average is 8.16EUR. The last closing price is up 13.49% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 1,522,310 shares of the stock were exchanged, down from an avg. volume of 2,024,700
With a total market value of 0 EUR, STRATEC Biomedical has price-earnings ratio of 15.59 with a one year low of 3.98EUR and a one year high of 9.83EUR .
A total of 3 equity analysts have released a research note on SBS. zero equity analysts rating the company a strong buy, zero equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of 28.48EUR.
More About STRATEC Biomedical (ETR:SBS)
STRATEC Biomedical AG (STRATEC) is a Germany-based company engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of clinical diagnostics and biotechnology. It is primarily active in the in vitro diagnostics industry and focuses on the segment in-vitro diagnostics, clinical diagnostics as well as molecular diagnostics. STRATEC's partners market Company's products to pharmaceutical laboratories, blood banks and research institutes throughout the world. STRATEC Group operats through its four consolidated subsidiaries in Switzerland, the United Kingdom, Germany as well as the United States, comprising STRATEC Biomedical Switzerland AG, STRATEC Biomedical UK, Ltd, STRATEC Molecular GmbH and STRATEC Biomedical USA, Inc.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.